• Je něco špatně v tomto záznamu ?

The natural history of primary sclerosing cholangitis in 781 children: A multicenter, international collaboration

MR. Deneau, W. El-Matary, PL. Valentino, R. Abdou, K. Alqoaer, M. Amin, AZ. Amir, M. Auth, F. Bazerbachi, A. Broderick, A. Chan, J. Cotter, S. Doan, M. El-Youssef, F. Ferrari, KN. Furuya, M. Gottrand, F. Gottrand, N. Gupta, M. Homan, BM. Kamath,...

. 2017 ; 66 (2) : 518-527. [pub] 20170626

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc17030895

There are limited data on the natural history of primary sclerosing cholangitis (PSC) in children. We aimed to describe the disease characteristics and long-term outcomes of pediatric PSC. We retrospectively collected all pediatric PSC cases from 36 participating institutions and conducted a survival analysis from the date of PSC diagnosis to dates of diagnosis of portal hypertensive or biliary complications, cholangiocarcinoma, liver transplantation, or death. We analyzed patients grouped by disease phenotype and laboratory studies at diagnosis to identify objective predictors of long-term outcome. We identified 781 patients, median age 12 years, with 4,277 person-years of follow-up; 33% with autoimmune hepatitis, 76% with inflammatory bowel disease, and 13% with small duct PSC. Portal hypertensive and biliary complications developed in 38% and 25%, respectively, after 10 years of disease. Once these complications developed, median survival with native liver was 2.8 and 3.5 years, respectively. Cholangiocarcinoma occurred in 1%. Overall event-free survival was 70% at 5 years and 53% at 10 years. Patient groups with the most elevated total bilirubin, gamma-glutamyltransferase, and aspartate aminotransferase-to-platelet ratio index at diagnosis had the worst outcomes. In multivariate analysis PSC-inflammatory bowel disease and small duct phenotypes were associated with favorable prognosis (hazard ratios 0.6, 95% confidence interval 0.5-0.9, and 0.7, 95% confidence interval 0.5-0.96, respectively). Age, gender, and autoimmune hepatitis overlap did not impact long-term outcome. CONCLUSION: PSC has a chronic, progressive course in children, and nearly half of patients develop an adverse liver outcome after 10 years of disease; elevations in bilirubin, gamma-glutamyltransferase, and aspartate aminotransferase-to-platelet ratio index at diagnosis can identify patients at highest risk; small duct PSC and PSC-inflammatory bowel disease are more favorable disease phenotypes. (Hepatology 2017;66:518-527).

Academic Medical Centre Amsterdam The Netherlands

Alder Hey Children's Hospital Liverpool UK

Children's Health Memorial Institute Warsaw Poland

Children's National Medical Center Washington DC

Columbia University College of Physicians and Surgeons New York NY

Emory University School of Medicine Atlanta GA

Lille University Hospital of Lille Lille France

Mayo Clinic Rochester MN

Mayo Clinic Rochester MN Nemours Alfred 1 duPont Hospital For Children Wilmington DE

Medical College of Wisconsin Milwaukee WI

Memorial University St John's Newfoundland and Labrador Canada

Northwest Pediatric Gastroenterology LLC Portland OR

Palacky University Olomouc Czech Republic

Prince Salman North West Armed Forces Hospital Tabuk Saudi Arabia

Sapienza University of Rome Rome Italy

Shaare Zedek Medical Center Jerusalem Israel

State University of New York Buffalo Buffalo NY

Teikyo University School of Medicine Tokyo Japan

Texas Children's Hospital Houston TX and Phoenix Children's Hospital Phoenix AZ

The Dana Dwek Children's Hospital The Tel Aviv Medical Center Tel Aviv University Tel Aviv Israel

University College Dublin Dublin Ireland

University of Alberta Edmonton Alberta Canada

University of Athens Athens Greece

University of California San Francisco San Francisco CA and Texas Children's Hospital Houston TX

University of Colorado School of Medicine Aurora CO

University of Helsinki Helsinki Finland

University of Liverpool Liverpool and University of Manchester Manchester UK

University of Ljubljana Ljubljana Slovenia

University of Manitoba Winnipeg Manitoba Canada

University of Naples Federico 2 Naples Italy

University of Pittsburgh Medical Center Pittsburgh PA

University of Rochester Medical Center Rochester NY

University of Toronto Toronto Ontario Canada

University of Ulsan Seoul South Korea

University of Utah Salt Lake City UT

Yale University School of Medicine New Haven CT

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17030895
003      
CZ-PrNML
005      
20171102120941.0
007      
ta
008      
171025s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/hep.29204 $2 doi
035    __
$a (PubMed)28390159
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Deneau, Mark R $u University of Utah, Salt Lake City, UT.
245    14
$a The natural history of primary sclerosing cholangitis in 781 children: A multicenter, international collaboration / $c MR. Deneau, W. El-Matary, PL. Valentino, R. Abdou, K. Alqoaer, M. Amin, AZ. Amir, M. Auth, F. Bazerbachi, A. Broderick, A. Chan, J. Cotter, S. Doan, M. El-Youssef, F. Ferrari, KN. Furuya, M. Gottrand, F. Gottrand, N. Gupta, M. Homan, BM. Kamath, KM. Kim, KL. Kolho, A. Konidari, B. Koot, R. Iorio, O. Ledder, C. Mack, M. Martinez, T. Miloh, P. Mohan, N. O'Cathain, A. Papadopoulou, A. Ricciuto, L. Saubermann, P. Sathya, E. Shteyer, V. Smolka, A. Tanaka, R. Varier, V. Venkat, B. Vitola, MB. Vos, M. Woynarowski, J. Yap, MK. Jensen,
520    9_
$a There are limited data on the natural history of primary sclerosing cholangitis (PSC) in children. We aimed to describe the disease characteristics and long-term outcomes of pediatric PSC. We retrospectively collected all pediatric PSC cases from 36 participating institutions and conducted a survival analysis from the date of PSC diagnosis to dates of diagnosis of portal hypertensive or biliary complications, cholangiocarcinoma, liver transplantation, or death. We analyzed patients grouped by disease phenotype and laboratory studies at diagnosis to identify objective predictors of long-term outcome. We identified 781 patients, median age 12 years, with 4,277 person-years of follow-up; 33% with autoimmune hepatitis, 76% with inflammatory bowel disease, and 13% with small duct PSC. Portal hypertensive and biliary complications developed in 38% and 25%, respectively, after 10 years of disease. Once these complications developed, median survival with native liver was 2.8 and 3.5 years, respectively. Cholangiocarcinoma occurred in 1%. Overall event-free survival was 70% at 5 years and 53% at 10 years. Patient groups with the most elevated total bilirubin, gamma-glutamyltransferase, and aspartate aminotransferase-to-platelet ratio index at diagnosis had the worst outcomes. In multivariate analysis PSC-inflammatory bowel disease and small duct phenotypes were associated with favorable prognosis (hazard ratios 0.6, 95% confidence interval 0.5-0.9, and 0.7, 95% confidence interval 0.5-0.96, respectively). Age, gender, and autoimmune hepatitis overlap did not impact long-term outcome. CONCLUSION: PSC has a chronic, progressive course in children, and nearly half of patients develop an adverse liver outcome after 10 years of disease; elevations in bilirubin, gamma-glutamyltransferase, and aspartate aminotransferase-to-platelet ratio index at diagnosis can identify patients at highest risk; small duct PSC and PSC-inflammatory bowel disease are more favorable disease phenotypes. (Hepatology 2017;66:518-527).
650    _2
$a analýza rozptylu $7 D000704
650    _2
$a jehlová biopsie $7 D001707
650    _2
$a dítě $7 D002648
650    _2
$a sklerozující cholangitida $x mortalita $x patologie $x chirurgie $7 D015209
650    _2
$a kohortové studie $7 D015331
650    _2
$a progrese nemoci $7 D018450
650    _2
$a přežití po terapii bez příznaků nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $7 D007150
650    _2
$a internacionalita $7 D038622
650    _2
$a Japonsko $7 D007564
650    _2
$a jaterní testy $7 D008111
650    _2
$a transplantace jater $x metody $x mortalita $7 D016031
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a multivariační analýza $7 D015999
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a analýza přežití $7 D016019
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a El-Matary, Wael $u University of Manitoba, Winnipeg, Manitoba, Canada.
700    1_
$a Valentino, Pamela L $u Yale University School of Medicine, New Haven, CT.
700    1_
$a Abdou, Reham $u State University of New York Buffalo, Buffalo, NY. $7 gn_A_00000408
700    1_
$a Alqoaer, Khaled $u Prince Salman North West Armed Forces Hospital, Tabuk, Saudi Arabia. $7 gn_A_00004788
700    1_
$a Amin, Mansi $u University of California San Francisco, San Francisco, CA, and Texas Children's Hospital, Houston, TX. $7 gn_A_00005585
700    1_
$a Amir, Achiya Z $u The Dana-Dwek Children's Hospital, The Tel-Aviv Medical Center, Tel-Aviv University, Tel Aviv, Israel. $7 gn_A_00005610
700    1_
$a Auth, Marcus $u Alder Hey Children's Hospital, Liverpool, UK. $7 gn_A_00010211
700    1_
$a Bazerbachi, Fateh $u Mayo Clinic, Rochester, MN.
700    1_
$a Broderick, Annemarie $u University College Dublin, Dublin, Ireland.
700    1_
$a Chan, Albert $u University of Rochester Medical Center, Rochester, NY.
700    1_
$a Cotter, Jillian $u University of Colorado School of Medicine, Aurora, CO.
700    1_
$a Doan, Sylvia $u University of Utah, Salt Lake City, UT.
700    1_
$a El-Youssef, Mounif $u Mayo Clinic, Rochester, MN.
700    1_
$a Ferrari, Federica $u Sapienza University of Rome, Rome, Italy.
700    1_
$a Furuya, Katryn N $u Mayo Clinic, Rochester, MN. Nemours Alfred I duPont Hospital For Children, Wilmington, DE.
700    1_
$a Gottrand, Madeleine $u Lille University Hospital of Lille, Lille, France.
700    1_
$a Gottrand, Frederic $u Lille University Hospital of Lille, Lille, France.
700    1_
$a Gupta, Nitika $u Emory University School of Medicine, Atlanta, GA.
700    1_
$a Homan, Matjaz $u University of Ljubljana, Ljubljana, Slovenia.
700    1_
$a Kamath, Binita M $u University of Toronto, Toronto, Ontario, Canada.
700    1_
$a Kim, Kyung Mo $u University of Ulsan, Seoul, South Korea.
700    1_
$a Kolho, Kaija-Leena $u University of Helsinki, Helsinki, Finland.
700    1_
$a Konidari, Anastasia $u University of Liverpool, Liverpool, and University of Manchester, Manchester, UK.
700    1_
$a Koot, Bart $u Academic Medical Centre, Amsterdam, The Netherlands.
700    1_
$a Iorio, Raffaele $u University of Naples Federico II, Naples, Italy.
700    1_
$a Ledder, Oren $u Shaare Zedek Medical Center, Jerusalem, Israel.
700    1_
$a Mack, Cara $u University of Colorado School of Medicine, Aurora, CO.
700    1_
$a Martinez, Mercedes $u Columbia University College of Physicians and Surgeons, New York, NY.
700    1_
$a Miloh, Tamir $u Texas Children's Hospital, Houston, TX, and Phoenix Children's Hospital, Phoenix, AZ.
700    1_
$a Mohan, Parvathi $u Children's National Medical Center, Washington, DC.
700    1_
$a O'Cathain, Niamh $u University College Dublin, Dublin, Ireland.
700    1_
$a Papadopoulou, Alexandra $u University of Athens, Athens, Greece.
700    1_
$a Ricciuto, Amanda $u University of Toronto, Toronto, Ontario, Canada.
700    1_
$a Saubermann, Lawrence $u University of Rochester Medical Center, Rochester, NY.
700    1_
$a Sathya, Pushpa $u Memorial University, St. John's, Newfoundland and Labrador, Canada.
700    1_
$a Shteyer, Eyal $u Shaare Zedek Medical Center, Jerusalem, Israel.
700    1_
$a Smolka, Vratislav $u Palacky University, Olomouc, Czech Republic.
700    1_
$a Tanaka, Atushi $u Teikyo University School of Medicine, Tokyo, Japan.
700    1_
$a Varier, Raghu $u Northwest Pediatric Gastroenterology LLC, Portland, OR.
700    1_
$a Venkat, Veena $u University of Pittsburgh Medical Center, Pittsburgh, PA.
700    1_
$a Vitola, Bernadette $u Medical College of Wisconsin, Milwaukee, WI.
700    1_
$a Vos, Miriam B $u Emory University School of Medicine, Atlanta, GA.
700    1_
$a Woynarowski, Marek $u Children's Health Memorial Institute, Warsaw, Poland.
700    1_
$a Yap, Jason $u University of Alberta, Edmonton, Alberta, Canada.
700    1_
$a Jensen, M Kyle $u University of Utah, Salt Lake City, UT.
773    0_
$w MED00009806 $t Hepatology (Baltimore, Md.) $x 1527-3350 $g Roč. 66, č. 2 (2017), s. 518-527
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28390159 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171102121034 $b ABA008
999    __
$a ok $b bmc $g 1254488 $s 991922
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 66 $c 2 $d 518-527 $e 20170626 $i 1527-3350 $m Hepatology $n Hepatology $x MED00009806
LZP    __
$a Pubmed-20171025

Najít záznam

Citační ukazatele

Možnosti archivace